Clinical Trials

Multiple Myeloma

NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

6 enrolled 5 charts

Multiple Myeloma, Recurrence

NCT03104842 2026-05-15

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

246 enrolled

Multiple Myeloma

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

208 enrolled 5 charts

Multiple Myeloma

NCT03319667 2026-05-04

IMROZ

475 enrolled 1 FDA

Multiple Myeloma

NCT04653246 2026-04-30

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

52 enrolled

Multiple Myeloma

NCT02960555 2026-04-15

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

61 enrolled

Smoldering Multiple Myeloma

NCT05873205 2026-04-02

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Other hematologic neoplasm

12 enrolled

Hematologic Neoplasms

NCT04835129 2026-03-27

IMPEDE

28 enrolled

Multiple Myeloma

NCT05690984 2026-03-16

EMAT

30 enrolled

Multiple Myeloma, Neoplasm, Residual

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

11 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

270 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03617731 2026-02-03

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

662 enrolled

Multiple Myeloma

NCT04430894 2026-01-29

KRDI in Transplant-Eligible MM

50 enrolled 20 charts

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

118 enrolled

Multiple Myeloma

NCT04850599 2025-12-18

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

5 enrolled

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

337 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT07217184 2025-10-15

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

30 enrolled

Multiple Myeloma

NCT05123131 2025-07-08

Isa-RVD

54 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT02332850 2025-05-01

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

83 enrolled

Multiple Myeloma, Recurrence

NCT04891809 2025-04-10

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

198 enrolled

Neoplasms, Plasma Cell

NCT04786028 2025-01-08

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

72 enrolled

Phase 1/2 Active not recruiting

Hematologic Diseases, Multiple Myeloma, Neoplasms

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT04934475 2024-11-07

MIDAS

791 enrolled